Adam Belfrage
Software Engineer
Johan Hartman
Chief Medical Officer, CO-FOUNDER, MD, PhD, Professor Karolinska Institutet
Stratipath brings together clinicians, researchers, AI scientists, developers and industry specialists on its mission to provide every patient with the right treatment at the right time.
Stratipath’s novel solutions are driven by a rigorous scientific development process based on state-of-the-art machine- and deep-learning methods. By providing fast, accessible, and cost-effective precision diagnostics, we aim to minimise over- and undertreatment and reduce healthcare costs, benefiting all of society.
Stratipath brings together clinicians, researchers, AI scientists, developers and industry specialists on its mission to provide every patient with the right treatment at the right time.
Stratipath’s novel solutions are driven by a rigorous scientific development process based on state-of-the-art machine- and deep learning methods. By providing fast, accessible, and cost-effective precision diagnostics, we aim to minimise over- and undertreatment, and reduce healthcare costs, benefiting all of society.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
Stratipath aims to enable precision medicine by providing novel prognostic and predictive information. By reducing the number of patients assigned to intermediate-risk groups in diagnostic pathology, Stratipath provides decision support for clinicians in their therapeutic decision-making.
We also offer pharma and biotech companies an accelerated path to patient stratification by identifying biomarker strategies and subgroups of patients that may benefit from specific therapies.
By providing fast, accessible, and cost-effective precision diagnostics, we aim to minimise over- and undertreatment, and reduce healthcare costs, benefiting all of society.
Stratipath develops effective and cost-efficient decision support tools to allow faster and more reproducible results with reduced risk of diagnostic errors. This contributes to a greater equality of care for all patients.
Additional board members are Stratipath co-founders Johan Hartman, Mattias Rantalainen and Fredrik Wetterhall.
